Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT04226313
Recruiting Not applicable

Self-sampling for Non-attenders to Cervical Cancer Screening

NCT04226313 · tracked via the Priya Life Science Czechia tracker
Phase
Not applicable
Started
2019-09-23
Last updated
2026-03-23

Condition(s) studied

Cervical CancerCervical DysplasiaHuman Papillomavirus Infection

Investigational drug(s) / intervention(s)

Self-sampling by Evalyn BrushSelf sampling by Evalyn Brush home or in GP´s clinic

Self-sampling by Evalyn Brush: Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.

Self sampling by Evalyn Brush home or in GP´s clinic: Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush

Study summary

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

Eligibility

Sex
FEMALE
Min age
30 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women with age 30-65 years; for arm A women \> 65 years are allowed * Women live in the Czech Republic. * Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C). * Women with completed informed consent. * Women capable of self-sampling of cervicovaginal swab. Exclusion Criteria: * Pregnant women. * Women with no sexual intercourse experience. * Women after hysterectomy including cervix.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Olomouc Olomouc Czechia Recruiting

More The Institute of Molecular and Translational Medicine, Czech Republic trials in Czechia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04226313 on ClinicalTrials.gov ↗ ← All trials in Czechia